
Why Hims & Hers Shares Dropped Despite Stellar Revenue Growth
Hims & Hers Health’s stock dropped 18% after reporting a 95% revenue increase to $481 million, due to concerns over gross margins. The resolution of a semaglutide shortage by the FDA jeopardizes the company’s compounded prescriptions, impacting revenue. Hims & Hers initially